ReviewDrugs & aging2004
Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer's disease: a review with methodological considerations.
Review in Drugs & aging, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A review of the methods used to estimate the cost of Alzheimer's disease in the United States.American journal of Alzheimer's disease and other dementias · 2011Pooled it
- Primary Care Provider Preferences on Dementia Training: A Qualitative Study.Journal of Alzheimer's disease : JAD · 2023Article
- Acceptability and Preliminary Effectiveness of a Remote Dementia Educational Training Among Primary Care Providers and Health Navigators.Journal of Alzheimer's disease : JAD · 2022Article
- Social Aspects of Dementia Prevention from a Worldwide to National Perspective: A Review on the International Situation and the Example of Italy.Behavioural neurology · 2019Review
- The economic burden of the care and treatment for people with Alzheimer's disease: the outlook for the Czech Republic.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2016Article
- Alzheimer disease. Donepezil and nursing home placement--benefits and costs.Nature reviews. Neurology · 2016Article
- Health economics and health policy issues in Alzheimer's disease.The journal of nutrition, health & aging · 2010Article
- Cost-effectiveness of drug therapies for Alzheimer's disease: A brief review.Neuropsychiatric disease and treatment · 2008Article
- Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics.Neuropsychiatric disease and treatment · 2007Article
- NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used?PharmacoEconomics · 2007Review
- Donepezil in Alzheimer's disease: an evidence-based review of its impact on clinical and economic outcomes.Core evidence · 2006Article
- Economic evaluation of rivastigmine in patients with Parkinson's disease dementia.PharmacoEconomics · 2006Article
- Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease.PharmacoEconomics · 2005Review
- Errors in self-reports of health services use: impact on alzheimer disease clinical trial designs.Alzheimer disease and associated disordersArticle
- Improving physician awareness of Alzheimer disease and enhancing recruitment: the Clinician Partners Program.Alzheimer disease and associated disordersArticle
- The economic cost of Alzheimer's disease: Family or public health burden?Dementia & neuropsychologiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholinesterase inhibitors have been available for the treatment of Alzheimer's disease since 1993. They have significantly positive effects on cognitive functioning and other domains of functional capacity, such as activities of daily life in terms of efficacy, but the clinical value of these effects are under discussion. Cholinesterase inhibitors may also influence behavioural and psychological symptoms in Alzheimer's disease. Cholinesterase inhibitors are also regarded as rather expensive and, therefore, the question of cost effectiveness is essential. Pharmacoeconomic evaluations of cholinesterase inhibitors have so far been conducted in retrospect on efficacy data from prospective randomised clinical trials combined with economic data from other sources. There are no published specific cost-effectiveness studies of cholinesterase inhibitors which prospectively collected empirical data on costs and outcomes. There is only one published randomised clinical trial with such empirical data with a cost consequence analysis design, indicating cost neutrality. Several types of models to describe the long-term effects have been published, indicating cost effectiveness. However, due to methodological considerations, the validity of these models is difficult to judge. A research agenda for the cost effectiveness of cholinesterase inhibitors is proposed, including long-term studies with empirical data on resource use, costs and outcomes, studies on quality of life, informal care and behavioural and psychological symptoms, combination and comparative studies on mild cognitive impairment.
Indexed as
Identifiers
15040756What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.